Saturday 17 October 2026
Export TOVX’s income statement to Excel — free account
Theriva Biologics, Inc.
TOVX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 96.4%, free cash flow grew 34.7% and total debt fell 1.16%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.21
0.00
0.00%
Follow TOVX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 6,387.50 | 3,587.50 | 127.50 | 92.50 | 62.50 | 65.00 | 9.75 | 5.00 | 1.14 | 0.17 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 23,975.00 | 9,187.50 | 5,250.00 | 212.50 | 187.50 | 425.00 | 110.00 | 31.50 | 17.00 | 2.03 | |||||
| People | |||||||||||||||
| People | Employees | 30 | 25 | 13 | 11 | 10 | 9 | 9 | 22 | 22 | 16 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (28) | (15) | (13) | (15) | (10) | (14) | (21) | (20) | (26) | (24) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (28) | (15) | (13) | (15) | (10) | (14) | (20) | (18) | (26) | (24) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (2,534.96) | (1,573.43) | (1,015.00) | (245.00) | (165.00) | (47.50) | (32.75) | (28.50) | (19.03) | (2.08) | |||||
| Cash flow | (2,583.43) | (1,422.82) | (693.94) | (210.84) | (160.11) | (26.44) | (31.12) | (29.48) | (12.56) | (1.37) | |||||
| Capex | (52.69) | (14.93) | (0.28) | 0.00 | (0.12) | (0.03) | (0.19) | (0.31) | 0.00 | 0.00 | |||||
| Free cash flow | (2,636.11) | (1,437.75) | (694.22) | (210.84) | (160.22) | (26.47) | (31.31) | (29.80) | (12.56) | (1.38) | |||||
| Book value | 208.24 | (240.14) | 568.63 | (16.06) | (99.21) | 134.17 | 84.54 | 57.37 | 14.14 | 1.27 | |||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 12 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (28) | (20) | (17) | (14) | (12) | (13) | (19) | (19) | (17) | (17) | ||||
| Capex | (1) | 0 | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | (28) | (20) | (17) | (14) | (12) | (13) | (19) | (19) | (17) | (17) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 2 | 8 | 26 | 11 | 5 | 65 | 38 | 21 | 9 | 7 | ||||
| Total debt | — | — | — | 0 | 0 | 1 | 0 | 0 | 0 | 2 | |||||
| Net debt | (19) | (17) | (29) | (15) | (6) | (66) | (42) | (23) | (12) | (11) | |||||
| Shareholders’ equity | 2 | (3) | 14 | (1) | (8) | 65 | 52 | 37 | 19 | 15 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (102.19) | (107.10) | (103.27) | (67.87) | (97.93) | (58.87) | (28.16) | (28.88) | (56.65) | (68.62) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (131.40) | (96.03) | (218.10) | (375.98) | |||||
| ROE | (315.96) | 3,813.26 | (1,013.87) | (1,245.72) | 158.60 | (83.73) | (34.16) | (41.33) | (91.57) | (146.58) | |||||
Negative figures in brackets.
Fiscal years to Dec 2010 · latest quarter Mar 2026
Charts ten years each
Theriva Biologics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GDTC CytoMed Therapeutics Limited | $10.3M | — (loss-making) | — (loss-making) | — | n/m | −27.39% (below 0%: shrinking) | 0.00% | — | Compare |
| BLRX BioLineRx Ltd. | $10.2M | — (loss-making) | — (loss-making) | −3.29% (below 0%: shrinking) | n/m | −1,827.71% (below 0%: shrinking) | 79.93% | (1,215.31%) | Compare |
| LTRN Lantern Pharma Inc. | $10.0M | — (loss-making) | — | — | n/m | +25.31% (above 0%: growing) | 0.00% | 0.00% | Compare |
| TOVX Theriva Biologics, Inc. | $9.7M | 0.1× | — | +33.08% (above 0%: growing) | n/m | +34.69% (above 0%: growing) | 100.00% | 0.00% | |
| BIVI BioVie Inc. | $9.6M | — (loss-making) | — | — | n/m | +26.50% (above 0%: growing) | 0.00% | 0.00% | Compare |
| LSTA Lisata Therapeutics, Inc. | $9.6M | — (loss-making) | — (loss-making) | −98.30% (below 0%: shrinking) | n/m | +33.04% (above 0%: growing) | 100.00% | 0.00% | Compare |
| VTGN VistaGen Therapeutics, Inc. | $9.5M | — (loss-making) | — (loss-making) | +504.92% (above 0%: growing) | n/m | +22.23% (above 0%: growing) | 100.00% | (904.34%) | Compare |
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR | $9.4M | — (loss-making) | — | — | n/m | +47.89% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MTVA MetaVia Inc. | $9.0M | — (loss-making) | — | — | n/m | −22.42% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $9.6M | — | — | −3.29% | — | +23.77% | 0.00% | 0.00% |
Theriva Biologics, Inc. (TOVX) key facts
- Theriva Biologics, Inc. (TOVX) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
- As of October 16, 2026, TOVX traded at $0.21, a market capitalization of $9.7 million.
- Return on equity was −146.6% and debt-to-equity 0.13.
Theriva Biologics, Inc. (TOVX) Latest News
No news at this impact. Lower the threshold for more.